FENNEC PHARMACEUTICALS INC
FENCNASDAQ🏆 #2344 by market capEarnings Aug 11 · PreUS Equity
$12.78▲ $2.16 (+16.93%)
Live1h—
24h▲ 16.9%
7d▲ 26.0%
14d▲ 27.3%
30d▲ 21.4%
1y▲ 55.1%
🏦Market Cap
$444M
Small Cap
📈Revenue Growth (YoY)
+33.8%
High Growth
📊Gross Margin
92.8%
High
💵FCF Margin
—
⚖️P/S Ratio
9.3x
Elevated
Otter Score
44
Weak
Trading Snapshot
- Day Range
- $12.63 – $13.02
- 52-Week Range
- $5.65 – $11.66
- Volume
- $3.59B
- Avg Volume
- $4.76B
- Shares Outstanding
- 34.7M
- Next Earnings
- Sep 14, 2026
Fundamentals Snapshot
- Annual Revenue
- $41M
- Last Q Revenue
- $11M
- P/E Ratio
- —
- P/S Ratio
- 9.3x
- EPS (TTM)
- $-0.28
- Dividend Yield
- —
Why Investors Own FENC
- ✓High-growth profile — revenue up +25.4% YoY with expanding US Equity exposure.
- ✓Healthy economics — 34% gross margin and 25% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$41M▲ +30.6% YoY
Gross Margin (TTM)
33.9%▲ +0.9% YoY
Operating Income (TTM)
$12M▲ +30.6% YoY
Free Cash Flow (TTM)
$10M▲ +30.6% YoY
About FENNEC PHARMACEUTICALS INC
A company profile for FENNEC PHARMACEUTICALS INC isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
44/100
Analyst Ratings
ⓘConsensus
Buy
12 analysts
Strong Buy3
Buy8
Hold1
Sell0
Strong Sell0
Ratings as of Aug 2026
Latest News & Updates
SeekingAlpha·10h ago
Fennec Pharmaceuticals Inc. (FENC) Q2 2026 Earnings Call Transcript
Fennec Pharmaceuticals Inc. (FENC) Q2 2026 Earnings Call August 11, 2026 8:30 AM EDTCompany ParticipantsRobert Andrade - Chief Financial OfficerJeffrey...
🛰️
Benzinga·16h ago
Fennec Pharmaceuticals Q2 EPS $0.05 Beats $0.02 Estimate, Sales $17.874M Beat $16.095M Estimate
Fennec Pharmaceuticals (NASDAQ:FENC) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $0.02 by 150 percent. This is a 145.45 percent increase over losses of $(0.11) per share